Download PDF
psychoneuro 2008; 34(6/07): 293-305
DOI: 10.1055/s-0028-1083831
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Liquordiagnostik der Multiplen Sklerose – Diagnose und Differenzialdiagnose

Modern cerebrospinal fluid analysis of Multiple Sclerosis – Diagnosis and differential diagnosisRegina Schläger1 , Matthias Mehling1 , 2 , Achim Gass1 , Jens Kuhle1 , 2
  • 1Neurologische Klinik, Universitätsspital, Basel (Schweiz)
  • 2Departement Biomedizin, Universitätsspital, Basel (Schweiz)
Further Information

Publication History

Publication Date:
31 July 2008 (online)

    Permissions and Reprints

Bei der Multiplen Sklerose handelt es sich um eine chronisch–entzündliche Erkrankung des zentralen Nervensystems mit funktionellen Defiziten vorwiegend aufgrund multipler demyelinisierender Läsionen unterschiedlichen Alters. Grundkonzept der Diagnosestellung ist der Nachweis einer Dissemination des Krankheitsprozesses in Bezug auf Ort und Zeit. Die diagnostischen Kriterien der Multiplen Sklerose wurden wiederholt revidiert. Der Artikel gibt einen Überblick über verschiedene Kriteriensysteme und diskutiert die derzeit verwendeten McDonald–Kriterien in ihrer revidierten Fassung von 2005. Die Diagnosestellung der Multiplen Sklerose beruht auf dem Ausschluss anderer entzündlicher, infektiöser, granulomatöser und hereditärer Erkrankungen, die nachfolgend skizziert werden. Ein klinischer Abklärungsalgorithmus bei Verdacht auf Multiple Sklerose wird vorgestellt. Im Rahmen der Diagnosestellung ist die Liquoranalyse essenziell, charakteristische Liquorbefunde und ihre Bedeutung werden diskutiert.

Multiple Sclerosis (MS) is defined as a chronic inflammatory disease of the central nervous system with functional deficits predominantly due to multiple demyelinated and axonal lesions of different age. The basic concept of diagnosis relies on confirming dissemination of the disease process in time and space. The diagnostic criteria of MS were revised several times, the article gives an overview over different sets of diagnostic criteria and discusses the most recent version of the McDonald criteria, 2005. Several inflammatory, infectious, granulomatous and hereditary diseases may resemble MS and have to be excluded in the diagnostic process. An algorithmic approach to patients with suspected MS is described. In diagnosing MS analysis of the cerebrospinal fluid (CSF) plays an essential role, characteristic findings in CSF and their significance are discussed.

Key words

Multiple sclerosis - diagnostic criteria - cerebrospinal fluid analysis

Literatur

  • 1 Allison RS, Millar JH.. Prevalence of disseminated sclerosis in Northern Ireland.  Ulster Med J. 1954;  23 1-27
    PubMedGoogle Scholar
  • 2 Andersson M, Alvarez–Cermeño J, Bernardi G. et al. . Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report.  J Neurol Neurosurg Psychiatry. 1994;  57 897-902
    PubMedGoogle Scholar
  • 3 Annunziata P, Giorgio A, De Santi L. et al. . Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing–remitting MS patients treated with interferon–beta.  J Neurol Sci. 2006;  244 97-102
    CrossrefPubMedGoogle Scholar
  • 4 Baranzini SE, Jeong MC, Butunoi C. et al. . B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions.  J Immunol. 1999;  163 5133-5144
    PubMedGoogle Scholar
  • 5 Barkhof F, Rocca M, Francis G. et al. . Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a.  Ann Neurol. 2003;  53 718-724
    CrossrefPubMedGoogle Scholar
  • 6 Charil A, Yousry TA, Rovaris M. et al. . MRI and the diagnosis of multiple sclerosis: expanding the concept of „no better explanation”.  Lancet Neurol. 2006;  5 841-852
    CrossrefPubMedGoogle Scholar
  • 7 Cole SR, Beck RW, Moke PS. et al. . The predictive value of CSF oligoclonal banding for MS 5 years after optic neuritis. Optic Neuritis Study Group.  Neurology. 1998;  51 885-887
    PubMedGoogle Scholar
  • 8 Colombo M, Dono M, Gazzola P. et al. . Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients.  J Immunol. 2000;  164 2782-2789
    PubMedGoogle Scholar
  • 9 Comi G, Filippi M, Barkhof F. et al. . Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.  Lancet. 2001;  357 1576-1582
    CrossrefPubMedGoogle Scholar
  • 10 Dalton CM, Brex PA, Miszkiel KA. et al. . Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis.  Ann Neurol. 2002;  52 47-53
    CrossrefPubMedGoogle Scholar
  • 11 Dujmovic I, Mesaros S. et al. . Primary progressive multiple sclerosis: clinical and paraclinical characteristics with application of the new diagnostic criteria.  Eur J Neurol. 2004;  11 439-444
    CrossrefPubMedGoogle Scholar
  • 12 Fassas A, Passweg JR, Pekmezovic T. et al. . Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.  J Neurol. 2002;  249 1088-1097
    PubMedGoogle Scholar
  • 13 Felgenhauer K, Reiber H.. The diagnostic significance of antibody specificity indices in multiple sclerosis and herpes virus induced diseases of the nervous system.  Clin Investig. 1992;  70 28-37
    CrossrefPubMedGoogle Scholar
  • 14 Filippi M, Rovaris M, Inglese M. et al. . Interferon beta–1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double–blind, placebo–controlled trial.  Lancet. 2004;  364 1489-1496
    CrossrefPubMedGoogle Scholar
  • 15 Filippini G, Comi GC, Cosi V. et al. . Sensitivities and predictive values of paraclinical tests for diagnosing multiple sclerosis.  J Neurol. 1994;  241 132-137
    PubMedGoogle Scholar
  • 16 Freedman MS, Thompson EJ, Deisenhammer F. et al. . Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement.  Arch Neurol. 2005;  62 865-870
    CrossrefPubMedGoogle Scholar
  • 17 Giovannoni G, Kieseier B, Hartung HP.. Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis.  J Neurol Neurosurg Psychiatry. 1998;  64
    PubMedGoogle Scholar
  • 18 Hickey WF.. Migration of hematogenous cells through the blood–brain barrier and the initiation of CNS inflammation.  Brain Pathol. 1991;  1 97-105
    PubMedGoogle Scholar
  • 19 Jacobs LD, Beck RW, Simon JH. et al. . Intramuscular interferon beta–1a therapy initiated during a first demyelinating event in multiple sclerosis.  N Engl J Med. 2000;  343 898-904
    CrossrefPubMedGoogle Scholar
  • 20 Kappos L, Polman CH, Freedman MS. et al. . Treatment with interferon beta–1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.  Neurology. 2006;  67 1242-1249
    CrossrefPubMedGoogle Scholar
  • 21 Keren FK.. College of American Pathologists. Cerebrospinal Fluid Survey M–B: Participant Summary Report. Northfield,IL: College of American Pathologists 2002: 6
    Google Scholar
  • 22 Korteweg T, Tintoré M, Uitdehaag B. et al. . MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow–up study.  Lancet Neurol. 2006;  5 221-227
    CrossrefPubMedGoogle Scholar
  • 23 Lefvert AK, Link H.. IgG production within the central nervous system: a critical review of proposed formulae.  Ann Neurol. 1985;  17 13-20
    CrossrefPubMedGoogle Scholar
  • 24 Link H, Tibbling G.. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis.  Scand J Clin Lab Invest. 1977;  37 397-401
    CrossrefPubMedGoogle Scholar
  • 25 Link H, Huang YM.. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness.  J Neuroimmunol. 2006;  180 17-28
    CrossrefPubMedGoogle Scholar
  • 26 Mancardi GL, Saccardi R, Filippi M. et al. . Autologous hematopoietic stem cell transplantation suppresses Gd–enhanced MRI activity in MS.  Neurology. 2001;  57 62-68
    PubMedGoogle Scholar
  • 27 Martinelli V, Comi G, Filippi M. et al. . Paraclinical tests in acute–onset optic neuritis: basal data and results of a short follow–up.  Acta Neurol Scand. 1991;  84 231-236
    PubMedGoogle Scholar
  • 28 McDonald WI, Compston A, Edan G. et al. . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis.  Ann Neurol. 2001;  50 121-127
    CrossrefPubMedGoogle Scholar
  • 29 Miller DH, Ormerod IE, Rudge P. et al. . The early risk of multiple sclerosis following isolated acute syndromes of the brainstem and spinal cord.  Ann Neurol. 1989;  26 635-639
    PubMedGoogle Scholar
  • 30 Ohman S, Ernerudh J, Forsberg P. et al. . Comparison of seven formulae and isoelectrofocusing for determination of intrathecally produced IgG in neurological diseases.  Ann Clin Biochem. 1992;  29 405-410
    PubMedGoogle Scholar
  • 31 Polman CH, Reingold SC, Edan G. et al. . Diagnostic criteria for multiple sclerosis: 2005 revisions to the „McDonald Criteria”.  Ann Neurol. 2005;  58 840-846
    CrossrefPubMedGoogle Scholar
  • 32 Poser CM, Paty DW, Scheinberg L. et al. . New diagnostic criteria for multiple sclerosis: guidelines for research protocols.  Ann Neurol. 1983;  13 227-231
    CrossrefPubMedGoogle Scholar
  • 33 Qin Y, Duquette P, Zhang Y. et al. . Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis.  J Clin Invest. 1998;  102 1045-1050
    CrossrefPubMedGoogle Scholar
  • 34 Reiber H, Felgenhauer K.. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system.  Clin Chim Acta. 1987;  163 319-328
    CrossrefPubMedGoogle Scholar
  • 35 Reiber H.. Flow rate of cerebrospinal fluid (CSF) – a concept common to normal blood–CSF barrier function and to dysfunction in neurological diseases.  J Neurol Sci. 1994;  122 189-203
    CrossrefPubMedGoogle Scholar
  • 36 Reiber H.. Die diagnostische Bedeutung neuroimmunologischer Reaktionsmuster im Liquor cerebrospinalis.  Lab Med. 1995;  19 444-462
    PubMedGoogle Scholar
  • 37 Reiber H, Ungefehr S, Jacobi C.. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis.  Mult Scler. 1998;  4 111-117
    CrossrefPubMedGoogle Scholar
  • 38 Reiber H, Peter JB.. Cerebrospinal fluid analysis: disease–related data patterns and evaluation programs.  J Neurol Sci. 2001;  184 101-122
    CrossrefPubMedGoogle Scholar
  • 39 Roström B, Link H, Norrby E.. Antibodies in oligoclonal immunoglobulins in CSF from patients with acute cerebrovascular disease.  Acta Neurol Scand. 1981;  64 225-240
    PubMedGoogle Scholar
  • 40 Schumacker GA, Beebe G, Kibler RF. et al. . Problems of experimental trials of therapy in multiple sclerosis.  Ann NY Acad Sci. 1965;  122 552-568
    PubMedGoogle Scholar
  • 41 Sindic CJ.. CSF analysis in multiple sclerosis.  Acta Neurol Belg. 1994;  94 103-111
    PubMedGoogle Scholar
  • 42 Sindic CJ, Van Antwerpen MP, Goffette S.. The intrathecal humoral immune response: laboratory analysis and clinical relevance.  Clin Chem Lab Med. 2001;  39 333-340
    CrossrefPubMedGoogle Scholar
  • 43 Söderström M, Ya–Ping J, Hillert J, Link H.. Optic neuritis: prognosis for multiple sclerosis from MRI, CSF, and HLA findings.  Neurology. 1998;  50 708-714
    CrossrefPubMedGoogle Scholar
  • 44 Stachan R, Wurster U.. Frequency of virus specific antibodies in clinically definite multiple sclerosis versus acute monosymptomatic opticus neuritis.  J lab Med. 1996;  20 515
    PubMedGoogle Scholar
  • 45 Stendahl–Brodin L, Link H.. Relation between benign course of multiple sclerosis and low–grade humoral immune response in cerebrospinal fluid.  J Neurol Neurosurg Psychiatry. 1980;  43 102-105
    PubMedGoogle Scholar
  • 46 Thompson EJ.. Proteins of the Cerebrospinal Fluid. New York: Elsevier, Academic Press 2005
    Google Scholar
  • 47 Thompson EJ, Keir G.. Laboratory investigation of cerebrospinal fluid proteins.  Ann Clin Biochem. 1990;  27 425-435
    PubMedGoogle Scholar
  • 48 Thompson EJ.. Cerebrospinal fluid.  J Neurol Neurosurg Psychiatry. 1995;  59 349-357
    PubMedGoogle Scholar
  • 49 Tintoré M, Rovira A, Río J. et al. . New diagnostic criteria for multiple sclerosis: application in first demyelinating episode.  Neurology. 2003;  60 27-30
    CrossrefPubMedGoogle Scholar
  • 50 Tourtellotte W.. On cerebrospinal fluid immunoglobulin–G (IgG) quotients in multiple sclerosis and other diseases. A review and a new formula to estimate the amount of IgG synthesized per day by the central nervous system.  J Neurol Sci. 1970;  10 279-304
    CrossrefPubMedGoogle Scholar
  • 51 Tourtellotte WW, Potvin AR, Fleming JO. et al. . Multiple sclerosis: measurement and validation of central nervous system IgG synthesis rate.  Neurology. 1980;  30 240-244
    PubMedGoogle Scholar
  • 52 Tumani H, Tourtellotte WW, Peter JB, Felgenhauer K.. Acute optic neuritis: combined immunological markers and magnetic resonance imaging predict subsequent development of multiple sclerosis. The Optic Neuritis Study Group.  J Neurol Sci. 1998;  155 44-49
    CrossrefPubMedGoogle Scholar
  • 53 Wiendl H, Kieseier BC, Gold R. et al. . Multiple Sklerose – Revision der neuen McDonald–Diagnosekriterien.  Nervenarzt. 2006;  1235 1235-1245
    PubMedGoogle Scholar
  • 54 Wolinsky JS. PROMiSe Study Group. . The diagnosis of primary progressive multiple sclerosis.  J Neurol Sci. 2003;  206 145-152
    CrossrefPubMedGoogle Scholar
  • 55 Wurster U.. Protein gradients in the cerebrospinal fluid and the calculation of intracerebral IgG synthesis.  J Neuroimmunol. 1988;  20 233-235
    CrossrefPubMedGoogle Scholar
  • 56 Wurster U, Rinke M.. Does glycosilation contribute to the oligoclonal appearance of intracerebrally synthesized IgG?.  Can J Neurol Sci. 1993;  4
    PubMedGoogle Scholar
  • 57 Wurster U.. Elektrophoreseverfahren – Nachweis und Bedeutung von oligoklonalen Banden. In: Zettl K, Lehmitz R, and Eilhard M, Hrsg. Klinische Liquordiagnostik. 2. Aufl. Berlin: de Gruyter 2005: 208-238
    Google Scholar
  • 58 Zeman AZ, Kidd D, McLean BN. et al. . A study of oligoclonal band negative multiple sclerosis.  J Neurol Neurosurg Psychiatry. 1996;  60 27-30
    PubMedGoogle Scholar

Korrespondenz

Dr. med. Regina Schlaeger

Universitätsspital Basel Abteilung für Neurologie

Petersgraben 4

4031 Basel (Schweiz)

Email: schlaegerr@uhbs.ch